Details for New Drug Application (NDA): 203791
✉ Email this page to a colleague
NDA 203791 describes SITAVIG, which is a drug marketed by Lnhc and is included in one NDA. There are three patents protecting this drug. Additional details are available on the SITAVIG profile page.
The generic ingredient in SITAVIG is acyclovir. There are fifty-six drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the acyclovir profile page.
The generic ingredient in SITAVIG is acyclovir. There are fifty-six drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the acyclovir profile page.
Medical Subject Heading (MeSH) Categories for 203791
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;BUCCAL | Strength | 50MG | ||||
| Approval Date: | Apr 12, 2013 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Jun 16, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF HERPES LABIALIS | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Jun 3, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF HERPES LABIALIS | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Mar 23, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF HERPES LABIALIS | ||||||||
Complete Access Available with Subscription
